Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)
-
Published:2022-07
Issue:
Volume:169
Page:1-9
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Li JiaruiORCID, Cheng Yuejuan, Bai Chunmei, Xu Jianming, Shen Lin, Li Jie, Zhou Zhiwei, Li Zhiping, Chi Yihebali, Yu Xianjun, Li Enxiao, Xu Nong, Liu Tianshu, Lou Wenhui, Bai Yuxian, Yuan Xianglin, Wang Xiuwen, Yuan Ying, Chen Jia, Guan Sha, Fan Songhua, Su Weiguo
Subject
Cancer Research,Oncology
Reference30 articles.
1. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol,2017 2. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site;Pavel;Neuroendocrinology,2016 3. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors;Jimenez-Fonseca;Cancer Metastasis Rev,2015 4. Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review;Chau;Eur J Cancer Care,2013 5. Gastroenteropancreatic neuroendocrine tumours;Modlin;Lancet Oncol,2008
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|